Call for worldwide withdrawal of tiotropium Respimat mist inhaler

BMJ (Online)

Volumn 345, Issue 7884, 2012, Pages

  Beasley, Richard ^a   Singh, Sonal ^b   Loke, Yoon K ^c   Enright, Paul ^d   Furberg, Curt D ^e  

^a MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^d UNIVERSITY OF ARIZONA   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; IPRATROPIUM BROMIDE; PLACEBO; TIOTROPIUM BROMIDE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; INHALER; META ANALYSIS (TOPIC); MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW (TOPIC); UNITED KINGDOM; UNITED STATES;

CHOLINERGIC ANTAGONISTS; DRUG RECALLS; HUMANS; NASAL SPRAYS; NEBULIZERS AND VAPORIZERS; SCOPOLAMINE DERIVATIVES;

EID: 84869808782     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e7390     Document Type: Editorial

References (14)

1. Anthonisen NR, Connett JE, Enright PL, Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002;166:333-9.
2. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:1439-50. [Erratum in JAMA 2009;301:1227-30.]
3. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54.
4. MedSafe. Tiotropium Handihaler datasheet. Ministry of Health, New Zealand, 2011. www.medsafe.govt.nz/profs/datasheet/s/Spirivacap.pdf.
5. Pulmonary-Allergy Drugs Advisory Committee Meeting, US Food and Drug Administration. Clinical briefing document. 2009. NDA 21-395. Spiriva Handihaler. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/ drugs/pulmonaryallergydrugsadvisorycommittee/ucm190463.pdf.
6. Singh S, Loke YK, Enright P, Furberg CD. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax 2012 published online 4 July.
7. Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011;342:d3215.
8. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;7:CD009285.
9. Van Noord JA, Cornelissen PJ, Aumann JL, Platz J, Mueller A, Fogarty C. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Respir Med 2009;103:22-9.
10. Loke YK, Singh S. Risks associated with tiotropium in chronic obstructive airways disease: overview of the evidence to date. Ther Adv Drug Saf 2012;3:123-31.
11. Dong YH, Lin HH, Shau WY, Wu YC, Chang CH, Lai MS. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomized controlled trials. Thorax 2012; published online 6 October.
12. Verhamme K, Afonso A, Romio S, Stricker B, Brusselle G, Sturkenboom M. Increased risk of mortality in COPD patients using tiotropium Respimat vs tiotropium Handihaler. European Respiratory Society Annual Scientific Meeting, September 2012. Abstract 196.
13. Cates CJ. Safety of tiotropium: indirect evidence suggests the Respimat inhaler is riskier than the Handihaler. BMJ 2011;342:d2970.
14. Ram FSF, Carvallho CR, White J. Clinical effectiveness of the Respimat inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices. Int J COPD 2011;6:129-39.